BACKGROUND/ OBJECTIVES: High a naevus counts and atypical naevi are risk factors for cutaneous melanoma. However, many individuals with a high-risk naevus phenotype do not develop melanoma. In this study, we describe the clinical and dermoscopic attributes of naevi associated with melanoma in a high-risk naevus phenotype population. METHODS: This single-centre, hospital-based case-control study included 54 prospectively enrolled adult patients ≥18 years old with a high-risk naevus phenotype (18 cases with a history of melanoma and 36 age- and gender-matched controls without a history of melanoma). We analysed clinical and dermoscopic images of the 20 largest naevi for each participant. RESULTS: Cases had a higher mean age than controls (48.2 vs. 39.1 years, P = 0.007) but there was no difference in the male-to-female ratio between groups. Nearly, all participants (97%) were Fitzpatrick skin type II or III. Naevi in cases were more likely to be truncal, (72.6% vs. 53.6%, P = 0.01), particularly anterior truncal, (29.2% vs. 14.4%, P < 0.001) and larger than 8 mm (17.4% vs. 7.8%%, P = 0.01) compared to controls. CASH score of naevi did not differ between groups. Naevi in cases were more likely to have a multicomponent dermoscopic pattern than in controls (18.4% vs. 12.6%, P = 0.02). CONCLUSION: Larger naevi, truncal naevi, and naevi, with a multicomponent dermoscopic pattern may be risk factors for melanoma among individuals with a high-risk naevus phenotype. Further studies are needed to validate these findings.
BACKGROUND/ OBJECTIVES: High a naevus counts and atypical naevi are risk factors for cutaneous melanoma. However, many individuals with a high-risk naevus phenotype do not develop melanoma. In this study, we describe the clinical and dermoscopic attributes of naevi associated with melanoma in a high-risk naevus phenotype population. METHODS: This single-centre, hospital-based case-control study included 54 prospectively enrolled adult patients ≥18 years old with a high-risk naevus phenotype (18 cases with a history of melanoma and 36 age- and gender-matched controls without a history of melanoma). We analysed clinical and dermoscopic images of the 20 largest naevi for each participant. RESULTS: Cases had a higher mean age than controls (48.2 vs. 39.1 years, P = 0.007) but there was no difference in the male-to-female ratio between groups. Nearly, all participants (97%) were Fitzpatrick skin type II or III. Naevi in cases were more likely to be truncal, (72.6% vs. 53.6%, P = 0.01), particularly anterior truncal, (29.2% vs. 14.4%, P < 0.001) and larger than 8 mm (17.4% vs. 7.8%%, P = 0.01) compared to controls. CASH score of naevi did not differ between groups. Naevi in cases were more likely to have a multicomponent dermoscopic pattern than in controls (18.4% vs. 12.6%, P = 0.02). CONCLUSION: Larger naevi, truncal naevi, and naevi, with a multicomponent dermoscopic pattern may be risk factors for melanoma among individuals with a high-risk naevus phenotype. Further studies are needed to validate these findings.
Authors: Sara Gandini; Francesco Sera; Maria Sofia Cattaruzza; Paolo Pasquini; Damiano Abeni; Peter Boyle; Carmelo Francesco Melchi Journal: Eur J Cancer Date: 2005-01 Impact factor: 9.162
Authors: Julie Gachon; Philippe Beaulieu; Jean Francois Sei; Johanny Gouvernet; Jean Paul Claudel; Michel Lemaitre; Marie Aleth Richard; Jean Jacques Grob Journal: Arch Dermatol Date: 2005-04
Authors: Veronique Bataille; Bernet S Kato; Mario Falchi; Jeffrey Gardner; Masayuki Kimura; Marko Lens; Ursula Perks; Ana M Valdes; Dot C Bennett; Abraham Aviv; Tim D Spector Journal: Cancer Epidemiol Biomarkers Prev Date: 2007-07 Impact factor: 4.254
Authors: Igor Adameyko; Francois Lallemend; Jorge B Aquino; Jorge A Pereira; Piotr Topilko; Thomas Müller; Nicolas Fritz; Anna Beljajeva; Makoto Mochii; Isabel Liste; Dmitry Usoskin; Ueli Suter; Carmen Birchmeier; Patrik Ernfors Journal: Cell Date: 2009-10-16 Impact factor: 41.582
Authors: C Karimkhani; A C Green; T Nijsten; M A Weinstock; R P Dellavalle; M Naghavi; C Fitzmaurice Journal: Br J Dermatol Date: 2017-06-12 Impact factor: 9.302